Top

Published in:

01-09-2020 | Coronavirus | COVID-19

Challenges and management of neurological and psychiatric manifestations in SARS-CoV-2 (COVID-19) patients

Authors: Alessandro Orsini, Martina Corsi, Andrea Santangelo, Antonella Riva, Diego Peroni, Thomas Foiadelli, Salvatore Savasta, Pasquale Striano

Published in: Neurological Sciences | Issue 9/2020

Abstract

COVID-19 is a pandemic caused by human coronavirus (HCoV) SARS-CoV-2, which originated in Wuhan, China, at the end of 2019 and spread globally during 2020. Due to the difficulty of clinical decision-making during this period, our study group reviewed current literature focusing on the neurological and psychiatric aspects of COVID-19. Despite the knowledge on this newly discovered virus which is constantly evolving, different pieces of evidence reported an association between COVID-19 and neurological symptoms like headache, dizziness, taste and smell disorders and complications involving the nervous system eventually triggered by the pathologic processes elicited by SARS-CoV-2. It seems that younger patients are less prone to develop severe forms of COVID-19. However, neurological signs have been reported in paediatric patients as well, and in some cases, the infection presented neurological sequelae. Furthermore, children with particular neurological diseases or treated with specific drugs (e.g. immune-suppressant therapies) must be carefully monitored during this pandemic. Neurologists should be aware of the main drug–drug interactions and the neurological side effects of COVID-19 treatments. Notably, adverse mental health impact has been reported in patients with SARS-CoV-2, which could be related either to the social strain or to the eventual neurotropic effects of the virus, which in other infections have been proven to promote the onset of psychiatric symptoms. Further, psychiatric population may be more vulnerable to the infection and at higher risk for adverse outcomes.

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W, China Novel Coronavirus Investigating and Research Team (2020) A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382(8):727–733CrossRefPubMedPubMedCentral

Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD, Chen J, Luo Y, Guo H, Jiang RD, Liu MQ, Chen Y, Shen XR, Wang X, Zheng XS, Zhao K, Chen QJ, Deng F, Liu LL, Yan B, Zhan FX, Wang YY, Xiao GF, Shi ZL (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 579(7798):270–273PubMedPubMedCentral

WHO. Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV) 2020. Available from: https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov). Accessed 7 June 2020

WHO: Coronavirus disease (COVID-19) Situation Report 138. June 6, 2020

Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, Tong S (2020) Epidemiology of COVID-19 among children in China. Pediatrics 145:e20200702CrossRefPubMed

Li J, Long X, Zhang Q, et al. (2020) Emerging evidence for neuropsycho-consequences of COVID-19. Curr Neuropharmacol. https://doi.org/10.2174/1570159X18666200507085335

Smith K, Ostinelli E, Cipriani A (2020) Covid-19 and mental health: a transformational opportunity to apply an evidence-based approach to clinical practice and research. Evid Based Ment Health 23. England:45–46. https://doi.org/10.1136/ebmental-2020-300155CrossRefPubMed

Holmes EA, O'Connor RC, Perry VH, Tracey I, Wessely S, Arseneault L, Ballard C, Christensen H, Cohen Silver R, Everall I, Ford T, John A, Kabir T, King K, Madan I, Michie S, Przybylski AK, Shafran R, Sweeney A, Worthman CM, Yardley L, Cowan K, Cope C, Hotopf M, Bullmore E (2020) Multidisciplinary research priorities for the COVID-19 pandemic: a call for action for mental health science. Lancet Psychiatry 7:547–560PubMedPubMedCentral

Panda PK, Sharawat IK (2020) COVID-19 (SARS-CoV-2 infection) and children: pediatric neurologist’s perspective. Indian J Pediatr 87(7):556–557. https://doi.org/10.1007/s12098-020-03326-8

10.

Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J et al (2020) SARS-CoV-2 infection in children. N Engl J Med 382(17):1663–1665PubMed

11.

Li YC, Bai WZ, Hashikawa T (2020) The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol 92(6):552–555. https://doi.org/10.1002/jmv.25728

12.

Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J', Yu T, Zhang X, Zhang L (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 395(10223):507–513PubMedPubMedCentral

13.

To KF, Lo AW (2004) Exploring the pathogenesis of severe acute respiratory syndrome (SARS): the tissue distribution of the coronavirus (SARS-CoV) and its putative receptor, angiotensin-converting enzyme 2 (ACE2). J Pathol 203(3):740–743PubMedPubMedCentral

14.

Dubé M, Le Coupanec A, Wong AHM, Rini JM, Desforges M, Talbot PJ (2018) Axonal transport enables neuron-to-neuron propagation of human coronavirus OC43. J Virol 92(17):e00404-18. https://doi.org/10.1128/JVI.00404-18

15.

Netland J, Meyerholz DK, Moore S, Cassell M, Perlman S (2008) Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. J Virol 82(15):7264–7275PubMedPubMedCentral

16.

Andries K, Pensaert MB (1980) Immunofluorescence studies on the pathogenesis of hemagglutinating encephalomyelitis virus infection in pigs after oronasal inoculation. Am J Vet Res 41(9):1372–1378PubMed

17.

Baig AM, Khaleeq A, Ali U, Syeda H (2020) Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms. ACS Chem Neurosci 11(7):995–998PubMed

18.

Wu Y, Xu X, Chen Z, et al (2020) Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun 87:18–22. https://doi.org/10.1016/j.bbi.2020.03.031

19.

Li YC, Bai WZ, Hashikawa T (2020) Response to commentary on “The neuroinvasive potential of SARS-CoV-2 may play a role in the respiratory failure of COVID-19 patients”. J Med Virol 92(7):707–709. https://doi.org/10.1002/jmv.25824

20.

Yin R, Feng W, Wang T, et al (2020) Concomitant neurological symptoms observed in a patient diagnosed with coronavirus disease 2019. J Med Virol. https://doi.org/10.1002/jmv.25888

21.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395(10223):497–506PubMedPubMedCentral

22.

Mao L, Jin H, Wang M, et al (2020) Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol 77(6):1–9. https://doi.org/10.1001/jamaneurol.2020.1127

23.

Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ (2020) COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395(10229):1033–1034PubMedPubMedCentral

24.

Bohmwald K, Galvez NMS, Rios M, Kalergis AM (2018) Neurologic alterations due to respiratory virus infections. Front Cell Neurosci 12:386PubMedPubMedCentral

25.

Asadi-Pooya AA, Simani L (2020) Central nervous system manifestations of COVID-19: a systematic review. J Neurol Sci 413:116832PubMedPubMedCentral

26.

Lechien JR, Chiesa-Estomba CM, De Siati DR, et al (2020) Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol 277(8):2251–2261. https://doi.org/10.1007/s00405-020-05965-1

27.

Giacomelli A, Pezzati L, Conti F, et al (2020) Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study. Clin Infect Dis. https://doi.org/10.1093/cid/ciaa330

28.

Xiang P, Xu XM, Gao LL, Wang HZ, Xiong HF, Li RH (2020) First case of 2019 novel coronavirus disease with encephalitis. ChinaXiv 202003:00015

29.

Moriguchi T, Harii N, Goto J, Harada D, Sugawara H, Takamino J, Ueno M, Sakata H, Kondo K, Myose N, Nakao A, Takeda M, Haro H, Inoue O, Suzuki-Inoue K, Kubokawa K, Ogihara S, Sasaki T, Kinouchi H, Kojin H, Ito M, Onishi H, Shimizu T, Sasaki Y, Enomoto N, Ishihara H, Furuya S, Yamamoto T, Shimada S (2020) A first case of meningitis/encephalitis associated with SARS-coronavirus-2. Int J Infect Dis 94:55–58PubMedPubMedCentral

30.

Poyiadji N, Shahin G, Noujaim D, Stone M, Patel S, Griffith B (2020) COVID-19-associated acute hemorrhagic necrotizing encephalopathy: CT and MRI features. Radiology 201187. https://doi.org/10.1148/radiol.2020201187

31.

Wu X, Wu W, Pan W, Wu L, Liu K, Zhang HL (2015) Acute necrotizing encephalopathy: an underrecognized clinicoradiologic disorder. Mediat Inflamm 2015:792578

32.

Wang H, Ma S (2008) The cytokine storm and factors determining the sequence and severity of organ dysfunction in multiple organ dysfunction syndrome. Am J Emerg Med 26(6):711–715PubMed

33.

Avula A, Nalleballe K, Narula N, Sapozhnikov S, Dandu V, Toom S, Glaser A, Elsayegh D (2020) COVID-19 presenting as stroke. Brain Behav Immun 87:115–119PubMedPubMedCentral

34.

Oxley TJ, Mocco J, Majidi S, Kellner CP, Shoirah H, Singh IP et alLarge-vessel stroke as a presenting feature of Covid-19 in the young. N Engl J Med 3822020:e60

35.

Klok FA, Kruip M, van der Meer NJM, Arbous MS, Gommers D, Kant KM et al (2020) Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 191:145–147PubMedPubMedCentral

36.

Lippi G, Plebani M, Henry BM (2020) Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clin Chim Acta 506:145–148PubMedPubMedCentral

37.

Iadecola C, Anrather J (2011) The immunology of stroke: from mechanisms to translation. Nat Med 17(7):796–808PubMedPubMedCentral

38.

Doobay MF, Talman LS, Obr TD, Tian X, Davisson RL, Lazartigues E (2007) Differential expression of neuronal ACE2 in transgenic mice with overexpression of the brain renin-angiotensin system. Am J Physiol Regul Integr Comp Physiol 292(1):R373–R381PubMed

39.

Zhao H, Shen D, Zhou H, Liu J, Chen S (2020) Guillain-Barre syndrome associated with SARS-CoV-2 infection: causality or coincidence? Lancet Neurol 19(5):383–384PubMedPubMedCentral

40.

Toscano G, Palmerini F, Ravaglia S, et al (2020) Guillain-Barré syndrome associated with SARS-CoV-2. N Engl J Med 382(26):2574–2576. https://doi.org/10.1056/NEJMc2009191

41.

Assini A, Benedetti L, Di Maio S, Schirinzi E, Del Sette M (2020) New clinical manifestation of COVID-19 related Guillain-Barrè syndrome highly responsive to intravenous immunoglobulins: two Italian cases. Neurol Sci. https://doi.org/10.1007/s10072-020-04484-5

42.

Oguz-Akarsu E, Ozpar R, Mirzayev H, et al (2020) Guillain-Barré syndrome in a patient with minimal symptoms of COVID-19 infection. Muscle Nerve. https://doi.org/10.1002/mus.26992

43.

Camdessanche JP, Morel J, Pozzetto B, Paul S, Tholance Y, Botelho-Nevers E (2020) COVID-19 may induce Guillain-Barré syndrome. Rev Neurol (Paris) 176(6):516–518

44.

Multiple Sclerosis International Federation. Global COVID-19 advice for people with MS https://www.msif.org/. Accessed 7 June 2020

45.

Brownlee W, Bourdette D, Broadley S, Killestein J, Ciccarelli O (2020) Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic. Neurology. 94:949–952PubMed

46.

Amor S, Baker D, Khoury SJ, Schmierer K, Giovanonni G (2020) SARS-CoV-2 and multiple sclerosis: not all immune depleting DMTs are equal or bad. Ann Neurol n/a(n/a)

47.

Winkelmann A, Loebermann M, Reisinger EC, Hartung HP, Zettl UK (2016) Disease-modifying therapies and infectious risks in multiple sclerosis. Nat Rev Neurol 12(4):217–233PubMed

48.

Guidon AC, Amato AA (2020) COVID-19 and neuromuscular disorders. Neurology 94:959–969PubMed

49.

Gummi RR, Kukulka NA, Deroche CB, Govindarajan R (2019) Factors associated with acute exacerbations of myasthenia gravis. Muscle Nerve 60(6):693–699PubMed

50.

Szperka CL, Ailani J, Barmherzig R, Klein BC, Minen MT, Halker Singh RB, Shapiro RE (2020) Migraine care in the era of COVID-19: clinical pearls and plea to insurers. Headache. 60(5):833–842PubMedPubMedCentral

51.

EMA gives advice on the use of non-steroidal anti-inflammatories for COVID-19

52.

Muller KI, Alstadhaug KB, Bekkelund SI (2017) A randomized trial of telemedicine efficacy and safety for nonacute headaches. Neurology. 89(2):153–162PubMedPubMedCentral

53.

Qubty W, Patniyot I, Gelfand A (2018) Telemedicine in a pediatric headache clinic: a prospective survey. Neurology 90(19):e1702–e17e5PubMed

54.

Bove R, Bevan C, Crabtree E, Zhao C, Gomez R, Garcha P, Morrissey J, Dierkhising J, Green AJ, Hauser SL, Cree BAC, Wallin MT, Gelfand JM (2019) Toward a low-cost, in-home, telemedicine-enabled assessment of disability in multiple sclerosis. Mult Scler 25(11):1526–1534PubMed

55.

Carlotti APdCP, Carvalho WBd, Johnston C, Rodriguez IS, Delgado AF (2020) COVID-19 diagnostic and management protocol for pediatric patients. Clinics 75

56.

Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S (2020) A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care 57:279–283PubMedPubMedCentral

57.

Gautret P, Lagier JC, Parola P, et al (2020) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 105949. https://doi.org/10.1016/j.ijantimicag.2020.105949

58.

Sun J, Chen Y, Fan X, Wang X, Han Q, Liu Z (2020) Advances in the use of chloroquine and hydroxychloroquine for the treatment of COVID-19. Postgrad Med:1–10. https://doi.org/10.1080/00325481.2020.1778982

59.

Chen J, Liu D, Liu L, Liu P, Xu Q, Xia L, Ling Y, Huang D, Song S, Zhang D, Qian Z, Li T, Shen Y, Lu H (2020) A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19. Zhejiang Da Xue Xue Bao Yi Xue Ban 49(2):215–219PubMedPubMedCentral

60.

Alhazzani W, Møller MH, Arabi YM, Loeb M, Gong MN, Fan E, Oczkowski S, Levy MM, Derde L, Dzierba A, du B, Aboodi M, Wunsch H, Cecconi M, Koh Y, Chertow DS, Maitland K, Alshamsi F, Belley-Cote E, Greco M, Laundy M, Morgan JS, Kesecioglu J, McGeer A, Mermel L, Mammen MJ, Alexander PE, Arrington A, Centofanti JE, Citerio G, Baw B, Memish ZA, Hammond N, Hayden FG, Evans L, Rhodes A (2020) Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Med 46(5):854–887PubMedPubMedCentral

61.

Agenzia Italiana del Farmaco (AIFA): AIFA sospende l’autorizzazione all’utilizzo di idrossiclorochina per il trattamento del COVID-19 al di fuori degli studi clinici

62.

Mulhauser P, Allemann Y, Regamey C (1995) Chloroquine and nonconvulsive status epilepticus. Ann Intern Med 123(1):76–77PubMed

63.

Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M et al (2020) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30. England:269–271PubMedPubMedCentral

64.

Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, Spitters C, Ericson K, Wilkerson S, Tural A, Diaz G, Cohn A, Fox L, Patel A, Gerber SI, Kim L, Tong S, Lu X, Lindstrom S, Pallansch MA, Weldon WC, Biggs HM, Uyeki TM, Pillai SK, Washington State 2019-nCoV Case Investigation Team (2020) First case of 2019 novel coronavirus in the United States. N Engl J Med 382(10):929–936PubMedPubMedCentral

65.

Russo EILClinically relevant drug-drug interaction between AEDs and medications used in the treatment of COVID-19 patients. Italian League Against Epilepsy

66.

Jean SS, Lee PI, Hsueh PR (2020) Treatment options for COVID-19: the reality and challenges. J Microbiol Immunol Infect 53(3):436–443. https://doi.org/10.1016/j.jmii.2020.03.034

67.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, Li X, Xia J, Chen N, Xiang J, Yu T, Bai T, Xie X, Zhang L, Li C, Yuan Y, Chen H, Li H, Huang H, Tu S, Gong F, Liu Y, Wei Y, Dong C, Zhou F, Gu X, Xu J, Liu Z, Zhang Y, Li H, Shang L, Wang K, Li K, Zhou X, Dong X, Qu Z, Lu S, Hu X, Ruan S, Luo S, Wu J, Peng L, Cheng F, Pan L, Zou J, Jia C, Wang J, Liu X, Wang S, Wu X, Ge Q, He J, Zhan H, Qiu F, Guo L, Huang C, Jaki T, Hayden FG, Horby PW, Zhang D, Wang C (2020) A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 382(19):1787–1799PubMed

68.

Brooks J, Daily J, Schwamm L (1997) Protease inhibitors and anticonvulsants. AIDS Clin Care 9(11):87–90PubMed

69.

May EF, Calvert PC (1990) Aggravation of myasthenia gravis by erythromycin. Ann Neurol 28(4):577–579PubMed

70.

AIFA. Sperimentazioni cliniche - COVID-19 [updated March 27, 2020. Available from: https://www.aifa.gov.it/-/covid-19-aggiornamento-studi-clinici-autorizzati. Accessed 7 June 2020

71.

CDC COVID-19 Response Team (2020) Coronavirus Disease 2019 in Children — United States, February 12–April 2, 2020. MMWR Morb Mortal Wkly Rep 69(14):422–426. https://doi.org/10.15585/mmwr.mm6914e4

72.

WHO. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19)

73.

Task force COVID-19 del Dipartimento Malattie Infettive e Servizio di Informatica, Istituto Superiore di Sanità. Epidemia COVID-19, Aggiornamento nazionale: 23 aprile 2020

74.

Cai J, Xu J, Lin D, et al (2020) A case series of children with 2019 novel coronavirus infection: clinical and epidemiological features. Clin Infect Dis. https://doi.org/10.1093/cid/ciaa198

75.

Xu Y, Li X, Zhu B, Liang H, Fang C, Gong Y, Guo Q, Sun X, Zhao D, Shen J, Zhang H, Liu H, Xia H, Tang J, Zhang K, Gong S (2020) Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. Nat Med 26(4):502–505PubMed

76.

Henry BM, Lippi G, Plebani M (2020) Laboratory abnormalities in children with novel coronavirus disease 2019. Clin Chem Lab Med 58(7):1135–1138. https://doi.org/10.1515/cclm-2020-0272

77.

Sun D, Li H, Lu XX, Xiao H, Ren J, Zhang FR, Liu ZS (2020) Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center’s observational study. World J Pediatr 16:251–259PubMed

78.

Tan X, Huang J, Zhao F, Zhou Y, Li JQ, Wang XY (2020) Clinical features of children with SARS-CoV-2 infection: an analysis of 13 cases from Changsha, China. Zhongguo Dang Dai Er Ke Za Zhi 22(4):294–298PubMed

79.

Streng A, Hartmann K, Armann J, Berner R, Liese JG (2020) COVID-19 bei hospitalisierten Kindern und Jugendlichen: Ein systematischer Review zu publizierten Fallserien (Stand 31.03.2020) und erste Daten aus Deutschland. [COVID-19 in hospitalized children and adolescents]. Monatsschr Kinderheilkd 1–12. https://doi.org/10.1007/s00112-020-00919-7

80.

Galea S, Merchant RM, Lurie N (2020) The mental health consequences of COVID-19 and physical distancing: the need for prevention and early intervention. JAMA Intern Med 180:817PubMed

81.

Gunnell D, Appleby L, Arensman E, Hawton K, John A, Kapur N, Khan M, O’Connor RC, Pirkis J, Appleby L, Arensman E, Caine ED, Chan LF, Chang SS, Chen YY, Christensen H, Dandona R, Eddleston M, Erlangsen A, Gunnell D, Harkavy-Friedman J, Hawton K, John A, Kapur N, Khan M, Kirtley OJ, Knipe D, Konradsen F, Liu S, McManus S, Mehlum L, Miller M, Moran P, Morrissey J, Moutier C, Niederkrotenthaler T, Nordentoft M, O’Connor RC, O’Neill S, Page A, Phillips MR, Pirkis J, Platt S, Pompili M, Qin P, Rezaeian M, Silverman M, Sinyor M, Stack S, Townsend E, Turecki G, Vijayakumar L, Yip PSF (2020) Suicide risk and prevention during the COVID-19 pandemic. Lancet Psychiatry 7:468–471PubMedPubMedCentral

82.

Severance EG, Dickerson FB, Viscidi RP, Bossis I, Stallings CR, Origoni AE, Sullens A, Yolken RH (2009) Coronavirus immunoreactivity in individuals with a recent onset of psychotic symptoms. Schizophr Bull 37(1):101–107PubMedPubMedCentral

83.

Okusaga O, Yolken RH, Langenberg P, Lapidus M, Arling TA, Dickerson FB, Scrandis DA, Severance E, Cabassa JA, Balis T, Postolache TT (2011) Association of seropositivity for influenza and coronaviruses with history of mood disorders and suicide attempts. J Affect Disord 130(1–2):220–225PubMed

84.

Liu N, Zhang F, Wei C, Jia Y, Shang Z, Sun L, Wu L, Sun Z, Zhou Y, Wang Y, Liu W (2020) Prevalence and predictors of PTSS during COVID-19 outbreak in China hardest-hit areas: gender differences matter. Psychiatry Res 287:112921PubMedPubMedCentral

85.

Tang W, Hu T, Hu B, Jin C, Wang G, Xie C, Chen S, Xu J (2020) Prevalence and correlates of PTSD and depressive symptoms one month after the outbreak of the COVID-19 epidemic in a sample of home-quarantined Chinese university students. J Affect Disord 274:1–7PubMedPubMedCentral

86.

Klomek AB (2020) Suicide prevention during the COVID-19 outbreak. Lancet Psychiatry 7(5):390PubMedPubMedCentral

87.

Kawohl W, Nordt C (2020) COVID-19, unemployment, and suicide. Lancet Psychiatry 7(5):389–390PubMedPubMedCentral

88.

Zambrelli E, Canevini M, Gambini O, D’Agostino A (2020) Delirium and sleep disturbances in COVID-19: a possible role for melatonin in hospitalized patients? Sleep Med 70:111PubMedPubMedCentral

Title: Challenges and management of neurological and psychiatric manifestations in SARS-CoV-2 (COVID-19) patients
Authors: Alessandro Orsini
Martina Corsi
Andrea Santangelo
Antonella Riva
Diego Peroni
Thomas Foiadelli
Salvatore Savasta
Pasquale Striano
Publication date: 01-09-2020
Publisher: Springer International Publishing
Keywords: Coronavirus
SARS-CoV-2
COVID-19
Published in: Neurological Sciences / Issue 9/2020
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-020-04544-w

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Challenges and management of neurological and psychiatric manifestations in SARS-CoV-2 (COVID-19) patients

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2020

Are patients with multiple sclerosis (MS) at higher risk of COVID-19 infection?

Electroencephalography during SARS-CoV-2 outbreak: practical recommendations from the task force of the Italian Society of Neurophysiology (SINC), the Italian League Against Epilepsy (LICE), and the Italian Association of Neurophysiology Technologists (AITN)

The prevalence of papilledema in patients with migraine: a crucial cooccurrence of migraine and idiopathic intracranial hypertension

Anti-CGRP in cluster headache therapy: a response

SMN1 gene copy number analysis for spinal muscular atrophy (SMA) in a Turkish cohort by CODE-SEQ technology, an integrated solution for detection of SMN1 and SMN2 copy numbers and the “2+0” genotype

Neck cooling induces blood pressure increase and peripheral vasoconstriction in healthy persons